Diabetic vascular disease: it's all the RAGE.
The major consequence of long-term diabetes is the increased incidence of disease of the vasculature. Of the underlying mechanisms leading to disease, the accumulation of advanced glycation end products (AGEs), resulting from the associated hyperglycemia, is the most convincing. Interaction of AGEs with their receptor, RAGE, activates numerous signaling pathways leading to activation of proinflammatory and procoagulatory genes. Studies in rodent models of macro- and microvascular disease have demonstrated that blockade of RAGE can prevent development of disease. These observations highlight RAGE as a therapeutic target for treatment of diabetic vascular disease.
Hudson
Barry I
BI
Department of Surgery, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA. bh2021@columbia.edu
Wendt
Thoralf
T
Bucciarelli
Loredana G
LG
Rong
Ling Ling
LL
Naka
Yoshifumi
Y
Yan
Shi Fang
SF
Schmidt
Ann Marie
AM
D000818:Animals; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D018450:Disease Progression; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000378:metabolism; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism*; D015398:Signal Transduction
D017127:Glycation End Products, Advanced; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic